GSK is forecasting a substantial expansion of its cancer-drug clinical pipeline, with the company expecting late-stage studies to nearly double next year, according to its oncology leadership and reporting by financial outlets.
Quartz and The Wall Street Journal both cite GSK’s oncology chief, who says the company has roughly 15 cancer assets in trials and could run about 19 to 20 late-stage studies in 2027. The Wall Street Journal also frames the update around GSK’s progress following a period of deals, noting it has five approved cancer medicines and a clinical-stage portfolio of about 15 assets.
Business Line also points to GSK’s planned growth trajectory, referencing that in July GSK expected more than 20 late-stage studies by the end of 2026. It adds that some of the drugs identified for faster development include cancer medicines, aligning with the overall message that oncology is a key focus of the pipeline build-out.
Taken together, the outlets largely agree on the scale of GSK’s oncology trials and the approximate number of assets in development, while differing on the emphasis—whether on next-year growth, prior guidance for end-2026, or the backdrop of dealmaking.
